Pankaj Bhargava, MD

Pankaj Bhargava serves as an Executive Partner at MPM Capital and previously served as the interim Chief Medical Officer of Aktis Oncology. Pankaj has been involved in drug development for over two decades, during which time he oversaw several functional areas, filed multiple INDs and led global registration programs and drug approvals in US, EU and other regions. Most recently, Pankaj served as Vice President and Head of the Oncology Therapeutic Area at Gilead Sciences where he was responsible for driving oncology strategy and execution across programs. In this role, he led the expansion of the oncology pipeline through multiple partnerships and acquisitions. He previously served as Chief Medical Officer at Dicerna Pharmaceuticals and Tioma Therapeutics (now ARCH oncology), and held roles with increasing responsibilities at Sanofi Oncology and AVEO Pharmaceuticals. Pankaj earned his MD from the University of Delhi and completed his training in medical oncology and clinical pharmacology at Georgetown University, Lombardi Cancer Center and NIH. Pankaj currently serves as a Clinical Assistant Professor at UCSF and was previously an Assistant Professor at Harvard Medical School and Dana-Farber Cancer Institute in Boston.